Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
Department of Medical Oncology, Dr. B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
Ann Hematol. 2019 Feb;98(2):437-443. doi: 10.1007/s00277-018-3525-0. Epub 2018 Oct 18.
Prognostic indices combining several clinical and laboratory parameters have been proposed for prognostication in chronic lymphocytic leukemia (CLL). Recently, international consortium on CLL proposed an international prognostic index (CLL-IPI) integrating clinical, molecular, and genetic parameters. The present study was designed to evaluate the reproducibility of CLL-IPI in Indian CLL cohort. The prognostic ability of CLL-IPI in terms of overall survival (OS) and time to first treatment (TTFT) was investigated in treatment-naive CLL patients and also compared with other existing prognostic scores. For assigning scores, clinical and laboratory details were obtained from medical records, and IGHV gene mutation status, β2-microglobulin levels, and copy number variations were determined using c-DNA, ELISA, and multiplex ligation-dependent probe amplification (MLPA), respectively. The scores were generated as per the weighted grades assigned to each variable involved in score categorization. The predictive value of prognostic models was assessed and compared using Harrell's C-index and Akaike's information criterion (AIC). Stratification of patients according to CLL-IPI yielded significant differences in terms of OS and TTFT (p < 0.001). Comparative assessment of scores for OS suggested better performance of CLL-IPI (C = 0.64, AIC = 740) followed by Barcelona-Brno (C = 0.61, AIC = 754) and MDACC score (C = 0.59, AIC = 759). Comparison of predictive value of prognostic scores for TTFT illustrated better performance of CLL-IPI (C = 0.72, AIC = 726) followed by Barcelona-Brno (C = 0.68, AIC = 743), modified GCLLSG (C = 0.66, AIC = 744), and O-CLL1 index (C = 0.55, AIC = 773). The results suggest better performance of CLL-IPI in terms of both OS and TTFT as compared to other available scores in our cohort.
用于预测慢性淋巴细胞白血病 (CLL) 预后的综合多种临床和实验室参数的预后指数已经被提出。最近,CLL 国际联合会提出了一个整合临床、分子和遗传参数的国际预后指数 (CLL-IPI)。本研究旨在评估 CLL-IPI 在印度 CLL 队列中的可重复性。在未经治疗的 CLL 患者中,根据总生存期 (OS) 和首次治疗时间 (TTFT) 评估了 CLL-IPI 的预后能力,并与其他现有的预后评分进行了比较。为了分配分数,从病历中获得了临床和实验室的详细信息,并且使用 c-DNA、ELISA 和多重连接依赖性探针扩增 (MLPA) 分别确定了 IGHV 基因突变状态、β2-微球蛋白水平和拷贝数变异。根据参与评分分类的每个变量的加权等级生成分数。使用 Harrell 的 C 指数和 Akaike 的信息准则 (AIC) 评估和比较了预测模型的预测价值。根据 CLL-IPI 对患者进行分层,在 OS 和 TTFT 方面有显著差异 (p<0.001)。对 OS 评分的比较评估表明,CLL-IPI 的性能更好 (C=0.64,AIC=740),其次是巴塞罗那-布诺 (C=0.61,AIC=754) 和 MDACC 评分 (C=0.59,AIC=759)。对 TTFT 预后评分预测价值的比较表明,CLL-IPI 的性能更好 (C=0.72,AIC=726),其次是巴塞罗那-布诺 (C=0.68,AIC=743)、改良 GCLLSG (C=0.66,AIC=744) 和 O-CLL1 指数 (C=0.55,AIC=773)。结果表明,与我们队列中的其他可用评分相比,CLL-IPI 在 OS 和 TTFT 方面的性能更好。